Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec 19:7:229.
doi: 10.1186/1471-2407-7-229.

The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma

Koh-ichi Sakata  1 , Masanori Someya, Mutsuko Omatsu, Hiroko Asanuma, Tadashi Hasegawa, Shingo Ichimiya, Masato Hareyama, Tetsuo Himi
Affiliations

The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma

Koh-ichi Sakata et al. BMC Cancer. .

Erratum in

  • BMC Cancer. 2008;8:45. Ichimiya, Shingo [added]

Abstract

Background: Nasal NK/T cell lymphoma is an aggressive disease and has a poor prognosis. Nasal NK/T cell lymphoma is refractory to conventional chemotherapy and has strong tendency of widespread relapse or dissemination into distant sites.

Methods: We immunohistochemically studied nasal NK/T-cell lymphoma to elucidate the unique characteristics of nasal NK/T-cell lymphoma, such as its higher metastatic tendency and its vast necrosis which leads to destruction of the involved tissues. The expression of P-glycoprotein and MMP-9 was evaluated in the 20 patients with nasal NK/T-cell lymphoma and 25 with nasal non-NK/T-cell lymphoma and the relationship between expression of these proteins and clinical results were analyzed in this report.

Results: Overall 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 51%, and 84%. Distant involvement free 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 53%, and 79%. Overall positivity for P-glycoprotein was observed in 10 of 19 patients with NTL and in 13 of 23 patients with non-NTL. When the overall survival rate was compared between patients with P-glycoprotein positive and negative, there was no difference between them. Sixteen of the 19 patients with nasal NK/T cell lymphoma expressed MMP-9. In contrast, only 8 of the 22 patients with nasal non-NK/T cell lymphoma expressed MMP-9. Distant involvement free 5-year survival rates for patients with MMP-9 negative, and MMP-9 positive were 92%, and 61%, respectively. The difference was statistically significant (p = 0.027).

Conclusion: Positive immunoreactivity for P-glycoprotein was not an independent prognostic factor in nasal NK/T-cell lymphomas, which stresses the importance of exploring other mechanisms of drug resistance. The strong expression of MMP-9 is uniquely characteristic of nasal NK/T cell lymphoma and may contribute to its strong tendency to disseminatate and the extensive necrosis which is always seen. However, our results are based on univariate comparisons, and as such, should be viewed with some caution.

PubMed Disclaimer

Figures

Figure 1
Figure 1
There was a deep ulcer in the middle of the hard palate with foul-smelling discharge (left photo). After radiotherapy, the tumor disappeared and deficit of the anterior palate appeared (right photo).
Figure 2
Figure 2
(a) The overall survival rates of patients of stage I or II with nasal NK/T cell lymphoma and nasal non-NK/T cell lymphoma. (b) The distant involvement free rates of patients of stage I or II with nasal NK/T cell lymphoma and nasal non-NK/T cell lymphoma.
Figure 3
Figure 3
(a) Expression of P-glycoprotein in nasal NK/T cell lymphoma (original magnification, ×200). (b) Expression of MMP-9 in nasal NK/T cell lymphoma (original magnification, ×200).
Figure 4
Figure 4
The overall survival rates of patients with B and T-cell lymphomas of stage I or II with P-glycoprotein positive or negative. All classifications of B and T-cell lymphomas were joined together and analyzed.
Figure 5
Figure 5
The distant involvement free rates of patients with B and T-cell lymphomasof stage I or II with MMP9 positive or negative. All classifications of B and T-cell lymphomas were joined together and analyzed.
See this image and copyright information in PMC

References

    1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.[comment] Blood. 1994;84:1361–1392. - PubMed
    1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.[comment] Journal of Clinical Oncology. 1999;17:3835–3849. - PubMed
    1. Aozasa K, Ohsawa M, Tajima K, Sasaki R, Maeda H, Matsunaga T, Friedmann I. Nation-wide study of lethal mid-line granuloma in Japan: frequencies of wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. International Journal of Cancer. 1989;44:63–66. doi: 10.1002/ijc.2910440112. - DOI - PubMed
    1. Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma. A clinicopathologic study with immunophenotypic and genotypic analysis. American Journal of Surgical Pathology. 1991;15:268–279. - PubMed
    1. Ho FC, Choy D, Loke SL, Kung IT, Fu KH, Liang R, Todd D, Khoo RK. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Human Pathology. 1990;21:1041–1050. doi: 10.1016/0046-8177(90)90254-3. - DOI - PubMed

MeSH terms

Substances